Biblio

Author Title [ Type

] Year

Filters: Author is Kröger, Nicolaus [Clear All Filters]

Journal Article

Niederwieser C, Iacobelli S, Franke G-N, Koster L, van Os M, Platzbecker U, Hübel K, Scheid C, Müller LPeter, Stelljes M, et al. Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC). Bone Marrow Transplant. 2024.

Gagelmann N, Wolschke C, Salit RB, Schroeder T, Ditschkowski M, Panagiota V, Cassinat B, Thol F, Badbaran A, Robin M, et al. Reduced intensity hematopoietic stem cell transplantation for myelofibrosis in accelerated-phase. Blood Adv. 2022.

Ayuk FAyuketang, Gagelmann N, von Tresckow B, Wulf GGeorg, Rejeski K, Stelljes M, Penack O, Baldus CD, Kröger N, Bethge WAndreas, et al. Real-world results of CAR-T cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study. Blood Adv. 2023.

Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, et al. Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.

Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, Giebel S, Greinix H, Hazenberg MD, Kröger N, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024.

Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2020;7(2):e157-e167.

Schieferdecker A, Shoshani O, Westner B, Zipori D, Fehse B, Kröger N, Ayuk F. Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins. Oncotarget. 2016.

Giebel S, Labopin M, Salmenniemi U, Socié G, Bondarenko S, Blaise D, Kröger N, Vydra J, Grassi A, Bonifazi F, et al. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors. A study from the Acute Leukemia Working Party of the Euro. Cancer. 2023.

Sahebi F, Eikema D-J, Koster L, Kröger N, Meijer E, van Doesum JA, Rovira M, Koc Y, Angelucci E, Blaise D, et al. Post-Transplant Cyclophosphamide for Graft vs Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type: A Study from the Chronic Malignancies Working Party of the EBM. Transplant Cell Ther. 2021.

van der Torren CR, van Hensbergen Y, Luther S, Aghai Z, Rychnavská ZStachová, Slot M, Scherjon S, Kröger N, Ganser A, Weissinger EM, et al. Possible Role of Minor H Antigens in the Persistence of Donor Chimerism after Stem Cell Transplantation; Relevance for Sustained Leukemia Remission. PLoS One. 2015;10(3):e0119595.

Robin C, Cordonnier C, Tridello G, Knelange N, Xhaard A, Chantepie S, Tanguy-Schmidt A, Schouten HC, Yesherun M, Rocha V, et al. Pneumocystis pneumonia after allogeneic hematopoietic cell transplantation: A case-control study on epidemiology and risk factors on behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Transplant Cell Ther. 2023.

Klyuchnikov E, Badbaran A, Massoud R, Freiberger P, Wolschke C, Ayuk F, Fehse B, Bacher U, Kröger N. Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR. Leukemia. 2024.

Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft H-G, Arseniev L, Beier R, Beutel G, Cario G, et al. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors. J Clin Invest. 2023.

Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen JJ, Andersen NS, Maillard N, Nguyen S, Blaise D, Deconinck E, et al. Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: a Study on Behalf of Eurocord and Cord Blood Committee of Celular Therapy and Immunobiology Working Party(CTIWP), Chronic Malignancies Working Pa. Biol Blood Marrow Transplant. 2015.

Ortí G, Gras L, Zinger N, Finazzi MChiara, Sockel K, Robin M, Forcade E, Avenoso D, Kröger N, Finke J, et al. Outcomes after Allogeneic Hematopoietic Cell Transplant in patients diagnosed with Blast Phase of Myeloproliferative Neoplasms: a retrospective study from the Chronic Malignancies Working Party of the EBMT. Am J Hematol. 2023.

Gurnari C, Gagelmann N, Badbaran A, Awada H, Dima D, Pagliuca S, D'Aveni-Piney M, Attardi E, Voso MTeresa, Cerretti R, et al. Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M. Leukemia. 2023.

Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, et al. OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT. Biol Blood Marrow Transplant. 2019.

Robin M, Porcher R, Wolschke C, de Fontbrune FSicre, Alchalby H, Christopeit M, Cassinat B, Zabelina T, de Latour RPeffault, Ayuk F, et al. Outcome after transplantation according to reduced intensity conditioning regimen in patients transplanted for myelofibrosis. Biol Blood Marrow Transplant. 2016.

Penack O, Peczynski C, Koenecke C, Polge E, Sanderson R, Yakoub-Agha I, Fegueux N, Daskalakis M, Collin M, Dreger P, et al. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. Front Immunol. 2023;14:1252811.

Barosi G, Tefferi A, Gangat N, Szuber N, Rambaldi A, Odenike O, Kröger N, Gagelmann N, Talpaz M, Kantarjian H, et al. Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024.

Gagelmann N, Bogdanov R, Stölzel F, Rautenberg C, Panagiota V, Becker H, Radujkovic A, Luft T, Christopeit M, Finke J, et al. Long-term survival benefit after allogeneic hematopoietic cell transplantation in chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2020.

Gowdavally S, Tsamadou C, Platzbecker U, Sala E, Valerius T, Klein S, Kröger N, Wulf G, Einsele H, Thurner L, et al. KIR2DS4 and its variant KIR1D in KIR-AA genotype donors showed differential survival impact in patients with lymphoid disease after HLA-matched unrelated hematopoietic stem cell transplantation. Transplant Cell Ther. 2023.

Kröger N. Induction, bridging or straight ahead the ongoing dilemma of allografting in advanced MDS. Biol Blood Marrow Transplant. 2019.

Klyuchnikov E, Langebrake C, Badbaran A, Dadkhah A, Massoud R, Freiberger P, Ayuk F, Janson D, Wolschke C, Bacher U, et al. Individualized busulfan dosing improves outcomes compared to fixed dose administration in pre-transplant MRD positive AML patients with intermediate risk undergoing allogeneic stem cell transplantation in CR. Eur J Haematol. 2022.

Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernández-Boluda JCarlos, et al. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2023.

Pages